Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Factors of Interest in Extended-Release Buprenorphine: Comparisons Between Incarcerated and Non-Incarcerated Patients with Opioid Use Disorder.
Chappuy M, Meroueh F, Trojak B, Bachellier J, Bendimerad P, Kosim M, Hjelmström P, Nubukpo P, Brousse G, Rolland B. Chappuy M, et al. Among authors: hjelmstrom p. Patient Prefer Adherence. 2021 Jun 14;15:1259-1267. doi: 10.2147/PPA.S311674. eCollection 2021. Patient Prefer Adherence. 2021. PMID: 34163143 Free PMC article.
What place for prolonged-release buprenorphine depot-formulation Buvidal® in the treatment arsenal of opioid dependence? Insights from the French experience on buprenorphine.
Vorspan F, Hjelmström P, Simon N, Benyamina A, Dervaux A, Brousse G, Jamain T, Kosim M, Rolland B. Vorspan F, et al. Among authors: hjelmstrom p. Expert Opin Drug Deliv. 2019 Sep;16(9):907-914. doi: 10.1080/17425247.2019.1649252. Epub 2019 Aug 23. Expert Opin Drug Deliv. 2019. PMID: 31364884
Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
Rolland B, Trojak B, Nourredine M, Bachellier J, Chappuy M, Bendimerad P, Kosim M, Hjelmström P, Meroueh F, Nubukpo P, Brousse G. Rolland B, et al. Among authors: hjelmstrom p. Drug Alcohol Depend. 2021 Mar 1;220:108492. doi: 10.1016/j.drugalcdep.2020.108492. Epub 2021 Jan 8. Drug Alcohol Depend. 2021. PMID: 33482572 Free article.
Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder.
Walsh SL, Comer SD, Zdovc JA, Sarr C, Björnsson M, Strandgården K, Hjelmström P, Tiberg F. Walsh SL, et al. Among authors: hjelmstrom p. Neuropsychopharmacology. 2024 May;49(6):1050-1057. doi: 10.1038/s41386-023-01793-z. Epub 2024 Jan 10. Neuropsychopharmacology. 2024. PMID: 38200140 Free PMC article.
Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
Lintzeris N, Dunlop AJ, Haber PS, Lubman DI, Graham R, Hutchinson S, Arunogiri S, Hayes V, Hjelmström P, Svedberg A, Peterson S, Tiberg F. Lintzeris N, et al. Among authors: hjelmstrom p. JAMA Netw Open. 2021 May 3;4(5):e219041. doi: 10.1001/jamanetworkopen.2021.9041. JAMA Netw Open. 2021. PMID: 33970256 Free PMC article. Clinical Trial.
Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.
Gunderson EW, Hjelmström P, Sumner M; 006 Study Investigators. Gunderson EW, et al. Among authors: hjelmstrom p. Clin Ther. 2015 Oct 1;37(10):2244-55. doi: 10.1016/j.clinthera.2015.08.025. Epub 2015 Sep 26. Clin Ther. 2015. PMID: 26412801 Free article. Clinical Trial.
53 results